Replies to post #2410 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA FY1Q23 CC transcript:

https://www.insidermonkey.com/blog/enanta-pharmaceuticals-inc-nasdaqenta-q1-2023-earnings-call-transcript-1117351/?singlepage=1

[DewDiligence]

ENTA FY2Q23* financials—3/31/23_pro_forma_ cash=$454M† :

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-35

FY2Q23 royalty revenue was $18.7M.

FY2Q23 R&D expenses were $43.5M, somewhat below the run rate for ENTA’s FY2023 guidance of $210-230M.

FY2Q23 SG&A expenses were $13.8M, slightly above the run rate for ENTA’s FY2023 guidance of $46-52M.

†Including $200M from partial monetization of Mavyret royalties and a $28.7M tax refund due from IRS.

*ENTA’s fiscal years end on September 30.